Does Rallies show Form 4 insider transactions for DBD?

Yes. Rallies tracks DBD insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is DBD research on Rallies investment advice?

No. Rallies provides research, data, and educational context for DBD. It does not provide personalized investment advice.

DBD (Diebold Nixdorf, Incorporated) Stock Analysis - Insider Trades

Diebold Nixdorf, Incorporated (DBD) is a publicly traded Technology sector company. As of May 21, 2026, DBD trades at $71.41 with a market cap of $2.39B and a P/E ratio of 27.98. DBD moved +4.20% today. Year to date, DBD is +9.27%; over the trailing twelve months it is +46.33%. Its 52-week range spans $34.88 to $89.05. Analyst consensus is buy with an average price target of $100.00. Rallies surfaces DBD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading DBD stock inside the company?

Recent DBD insider activity includes Millstreet Capital Management LLC sold 60.83K, Millstreet Capital Management LLC sold 51.47K, Millstreet Capital Management LLC sold 399.93K, Millstreet Capital Management LLC sold 500.00K, and Millstreet Capital Management LLC sold 40.52K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

DBD Key Metrics

Key financial metrics for DBD
Metric	Value
Price	$71.41
Market Cap	$2.39B
P/E Ratio	27.98
EPS	$2.57
Dividend Yield	0.00%
52-Week High	$89.05
52-Week Low	$34.88
Volume	2
Avg Volume	0
Revenue (TTM)	$3.81B
Net Income	$97.50M
Gross Margin	25.26%

Recent DBD Insider Trades

Millstreet Capital Management LLC sold 60.83K (~$5.16M) on Apr 16, 2026.
Millstreet Capital Management LLC sold 51.47K (~$4.40M) on Apr 15, 2026.
Millstreet Capital Management LLC sold 399.93K (~$32.96M) on Apr 8, 2026.
Millstreet Capital Management LLC sold 500.00K (~$34.00M) on Jan 15, 2026.
Millstreet Capital Management LLC sold 40.52K (~$2.61M) on Nov 6, 2025.

Latest DBD News

Diebold Nixdorf to Modernize 200+ VyStar ATMs with AI-Driven Branch Automation — May 5, 2026
Diebold Nixdorf Secures First-Time BB- Rating with Stable Outlook — Apr 23, 2026
Diebold Nixdorf to Join S&P SmallCap 600 Index on April 10, 2026 — Apr 10, 2026
Diebold Nixdorf Wins Three 2026 Europe Awards for ATM Services and Payment Innovation — Mar 5, 2026
Diebold Nixdorf Shares Surge 11.1% While Q1 EPS Estimate Slashed 17.6% — Mar 4, 2026

DBD Analyst Consensus

2 analysts cover DBD: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $100.00.

Common questions about DBD

Who is trading DBD stock inside the company?: Recent DBD insider activity includes Millstreet Capital Management LLC sold 60.83K, Millstreet Capital Management LLC sold 51.47K, Millstreet Capital Management LLC sold 399.93K, Millstreet Capital Management LLC sold 500.00K, and Millstreet Capital Management LLC sold 40.52K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for DBD?: Yes. Rallies tracks DBD insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is DBD research on Rallies investment advice?: No. Rallies provides research, data, and educational context for DBD. It does not provide personalized investment advice.